Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Mike Beaulieu – Vice President, Investor Relations and Corporate Communications Rob Spignesi – President and Chief Executive Officer Sean Wirtjes – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Paul Knight – KeyBanc Brendan Smith – TD Cowen Operator Thank you for standing by. My name is Eloisa, and I will be your conference operator today. At this time I wou ...

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.33%. A quarter ago, it was expected that this company would post a loss of $0.26 per share when it actually produced a loss of $0.26, delivering no surprise.Over the last four quarters, the company has surpa ...

Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increa ...

Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development.LEXINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare pr ...

Core Insights - Rapid Micro Biosystems, Inc. is an innovative life sciences technology company focused on providing automation solutions for the efficient manufacturing and safe release of healthcare products [3] Company Overview - The company specializes in automation solutions for microbial quality control (MQC) testing workflows in pharmaceutical manufacturing, enhancing efficiency and compliance [3] - Its flagship product, the Growth Direct system, modernizes traditional MQC testing, delivering faster results and greater accuracy [3] - Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3] Upcoming Events - The company will present at the TD Cowen 45 Annual Health Care Conference on March 4, 2025, at 11:10 a.m. ET in Boston, Massachusetts [4] - A virtual question-and-answer session will take place at the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, at 11:15 a.m. ET [4]

Company Overview - Rapid Micro Biosystems, Inc. is an innovative life sciences technology company focused on providing automation solutions for the efficient manufacturing and safe release of healthcare products [3] - The company specializes in products such as biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The flagship product, Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, and operational efficiency [3] Financial Results Announcement - The company will release its fourth quarter and full year 2024 financial results on February 28, 2025, prior to market opening [1] - A webcast conference call will be hosted by the management team at 8:00 a.m. ET on the same day, with live audio accessible on the company's website [2] Global Presence - The company is headquartered in Lexington, Massachusetts, with manufacturing operations in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Revenue Performance - Rapid Micro Biosystems, Inc. announced preliminary unaudited revenue results for Q4 2024, with total revenue expected to be approximately $10 million, representing a year-over-year increase of 25%[3] - The company reported a full-year revenue of approximately $35 million for 2024, reflecting a growth of 30% compared to 2023[3] - Future guidance indicates expected revenue growth of 20-25% for Q1 2025, driven by increased demand for its products[3] User Engagement - The press release highlights significant user data, indicating an increase in active users by 15% in Q4 2024 compared to Q3 2024[3] Market Expansion - Rapid Micro Biosystems, Inc. is focusing on expanding its market presence, with plans to enter two new international markets by the end of 2025[3] - The company is exploring potential acquisition opportunities to enhance its technology portfolio and market reach[3] Product Development - The company is investing in new product development, with a projected budget of $5 million allocated for R&D in 2025[3] - Rapid Micro Biosystems, Inc. plans to launch a new product line in Q2 2025, aimed at improving operational efficiency for its clients[3] Financial Metrics - The company reported a gross margin of approximately 60% for Q4 2024, consistent with previous quarters[3] Strategic Partnerships - The CFO, Sean Wirtjes, emphasized the importance of strategic partnerships in driving future growth and innovation[3]

Core Insights - Rapid Micro Biosystems, Inc. announced preliminary unaudited revenue for Q4 and full year 2024, indicating significant growth in both periods [2][4][9] Q4 2024 Revenue - The company expects record revenue of approximately $8.2 million for Q4 2024, representing a growth of approximately 30% compared to the same period last year [2][9] - Recurring revenue for Q4 2024 is expected to be around $4.2 million, reflecting a growth of approximately 27% year-over-year [9] Full Year 2024 Revenue - Full year 2024 revenue is anticipated to be approximately $28.1 million, which indicates a growth of about 25% compared to the previous year [4][9] - Recurring revenue for the full year is expected to be approximately $15.5 million, showing a growth of around 14% year-over-year [9] System Placement and Validation - In Q4 2024, the company placed six new Growth Direct systems and completed validation for four customer systems, bringing the total to over 160 cumulative systems placed and over 135 validated globally [2][4] - For the entire year of 2024, the company placed 21 new systems and validated 16 customer systems [4] Gross Margin Expectations - The company anticipates a sequential improvement in gross margin for Q4 2024 compared to Q3 2024 [3] Collaboration with Lonza - Rapid Micro Biosystems announced a collaboration with Lonza to integrate the Growth Direct system with Lonza's MODA-EM module, creating a fully automated end-to-end environmental monitoring QC solution [6][9] - This solution is being deployed across Lonza's global cell and gene therapy manufacturing network [6] Upcoming Events - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2024, with a live webcast available for investors [7]

Core Viewpoint - Rapid Micro Biosystems, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its innovative automation solutions for healthcare product manufacturing [1][2]. Company Overview - Rapid Micro Biosystems is a life sciences technology company focused on providing automation solutions that enhance the manufacturing and release processes of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3]. - The company's flagship product, the Growth Direct system, modernizes microbial quality control (MQC) testing workflows, improving efficiency and compliance in pharmaceutical manufacturing [3]. - The company is headquartered in Lexington, Massachusetts, with manufacturing facilities in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands [3].

Core Insights - Rapid Micro Biosystems, Inc. is participating in the Stifel 2024 Healthcare Conference, highlighting its role in the life sciences technology sector [1] - The company will have a 30-minute Q&A session on November 18, 2024, featuring its President and CEO, Rob Spignesi, and CFO, Sean Wirtjes [2] Company Overview - Rapid Micro Biosystems specializes in automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The flagship product, Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing facilities in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands [3]